A lthough initial results with liver transplantation for primary liver tumors were disappointing, the classic article by Mazzaferro et al from Milan reported that patients with cirrhosis and small-sized hepatocellular carcinoma (HCC) (a single HCC Յ5 cm in diameter or 3 or fewer tumors Յ3 cm in diameter) had 83% overall patient survival and 75% overall recurrence-free survival at 4 years. 1 The United Network for Organ Sharing (UNOS) subsequently adopted the same criteria for listing patients for deceased donor liver transplantation. With over 16,000 new cases of HCC diagnosed annually in the United States and a rising incidence particularly in young people related to hepatitis C, 2 selection of patients for liver transplantation requires discriminating criteria. That is because about 5000 patients undergo liver transplantation annually for all diseases. The introduction of living donor liver transplantation (LDLT), the use of extended criteria deceased donors, and the splitting of deceased donor livers are strategies implemented to address the growing disparity between supply and demand for donor livers. Two articles in this issue address different aspects of appropriate application of liver transplantation to the treatment of HCC.
The group from Mount Sinai Hospital in New York, responsible for one of the largest series of LDLTs in the United States, summarizes their experience in all 36 patients undergoing LDLT for HCC between 1998 and 2002. Outcomes are compared with 165 patients undergoing deceased donor liver transplantation at their center between 1992 and 2002. Their principal findings are: (1) waiting time between evaluation and transplantation was considerably shorter for LDLT recipients than for deceased donor recipients; (2) there were no significant differences in survival or recurrence of cancer between recipients of living donor and deceased donor grafts; (3) pretransplant treatment had no significant effect on the incidence of recurrence; and (4) LDLT for HCC was associated with significant perioperative recipient mortality (8 of 36). It is worth noting that 53% of the patients in the Mount Sinai series had tumors exceeding the UNOS criteria. With respect to the first of these observations, it is pertinent to note that as of February 2002, UNOS adopted a new allocation system for deceased donor livers based on modified end-stage liver disease (MELD) scores. Under the new system, candidates with HCC receive increased priority, and this has led to a significant increase in transplantation rates for patients with HCC. During the first 11 months of the new system, almost 800 patients were transplanted with an exceptional case MELD score due to a reported diagnosis of HCC. Fully 23% of deceased donor liver transplants were performed for candidates who received extra priority due to HCC. 3 Thus, while a benefit of shorter time to transplantation may continue to exist for LDLT versus deceased donor liver transplantation as reported by the Mount Sinai group, the differences in the current allocation system are not nearly as disparate as under the previous allocation system. Current discussion within UNOS centers around the observation that early (stage I) HCC remains stable for at least 1 year and does not merit extra priority for deceased donor liver transplantation. 4 However, during the first year of the MELD system allocation in the United States, 82% of the transplants for HCC were performed for patients for whom stage II priority was requested. 3 Appropriate liver allocation needs to be based on natural history data and sensitive and specific diagnostic tests. So far, size of tumor by CT scan has been used for preoperative staging since size has been reported to correlate with vascular invasion, 5 with progression of tumor, 4 and with recurrence rate after transplantation. 1, 6, 7 Nevertheless, better predictors for posttransplant recurrence and survival are valuable, and the contribution of Cillo et al of the University of Padua in this issue addresses the use of pretransplant liver tumor biopsy to select moderately or well-differentiated HCC. Based on 33 patients without extrahepatic spread and pretransplant biopsies showing no vascular invasion or grade 3 HCC (only grade 1 or 2 accepted), 5-year survival of 75% and recurrence-free survival of 92% was achieved. 8 These excellent results suggest that pretransplant knowledge of HCC grade may be useful for guiding selection of appropriate recipients. Other studies have cautioned against the use of biopsy due to risk of tumor seeding. 9 One difference between the Padua and the North American experiences is the frequent use of pretransplant and posttransplant chemotherapy in the Padua series, with 94% of patients treated preoperatively and 44% postoperatively. The appropriate role of adjunctive therapies including resection, radiofrequency ablation, cryoablation, transarterial chemoembolization, systemic chemotherapy, and percutaneous ethanol injection remains to be defined by larger controlled studies. Clearly there is a role for studies employing larger databases, and prospective, randomized, and multicenter trials. The contributions of the Scientific Registry of Transplant Recipients (SRTR) based on UNOS/ Organ Procurement and Transplantation Network (OPTN) data will continue to bring value to these discussions.
Whether LDLT is justified for patients whose tumors exceed criteria established or optimal outcomes in deceased donor liver transplantation remains a subject open to ethical debate since donor livers would not be removed from the generally available pool for recipients. The challenge is to balance the demands of treating HCC, especially if it exceeds UNOS criteria, with the known risk to a living donor. To guard against liberal use in patients with advanced HCC and expected poor outcomes, it seems reasonable to apply the same or similar criteria as used for allocation of deceased donor livers. Although the living donor may wish to maintain the freedom to choose, allocation policy for deceased donor livers will rely on the growing body of data on which to base the important decision of recipient selection in patients with known or suspected HCC.
